John Rogers's BIO Position Overview
John Rogers (via Ariel Investments, LLC) currently holds 809,480 shares of Bio-Rad Laboratories, Inc. (BIO) worth $226.97 M, representing 2.43% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, John Rogers has maintained a long-term strategic position in BIO, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2024, adding 274,508 shares. Largest reduction occurred in Q4 2017, reducing 256,724 shares.
Analysis based on 13F filings available since 2013 Q2
John Rogers's Bio-Rad Laboratories (BIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bio-Rad Laboratories (BIO) Trades by John Rogers
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +1.01 M | Add 0.00% | 1.01 M | $112.20 |
| Q3 2013 | +84,207 | Add 8.32% | 1.1 M | $117.56 |
| Q4 2013 | +5,994 | Add 0.55% | 1.1 M | $123.61 |
| Q1 2014 | -77,878 | Reduce 7.06% | 1.02 M | $128.12 |
| Q2 2014 | -41,277 | Reduce 4.03% | 983,452 | $119.71 |
| Q3 2014 | +83,774 | Add 8.52% | 1.07 M | $113.40 |
| Q4 2014 | -6,659 | Reduce 0.62% | 1.06 M | $120.56 |
| Q1 2015 | +80,575 | Add 7.60% | 1.14 M | $135.18 |
| Q2 2015 | -18,159 | Reduce 1.59% | 1.12 M | $150.61 |
| Q3 2015 | -122,822 | Reduce 10.94% | 1 M | $134.31 |
| Q4 2015 | +5,786 | Add 0.58% | 1.01 M | $138.66 |
| Q1 2016 | -1,455 | Reduce 0.14% | 1 M | $136.72 |
| Q2 2016 | -23,641 | Reduce 2.35% | 980,851 | $143.02 |
| Q3 2016 | -22,805 | Reduce 2.33% | 958,046 | $163.81 |
| Q4 2016 | -71,219 | Reduce 7.43% | 886,827 | $182.28 |
| Q1 2017 | -212,467 | Reduce 23.96% | 674,360 | $199.34 |
| Q2 2017 | -100,123 | Reduce 14.85% | 574,237 | $226.31 |
| Q3 2017 | -49,993 | Reduce 8.71% | 524,244 | $222.22 |
| Q4 2017 | -256,724 | Reduce 48.97% | 267,520 | $238.67 |
| Q1 2018 | -16,391 | Reduce 6.13% | 251,129 | $250.08 |
| Q2 2018 | -19,153 | Reduce 7.63% | 231,976 | $288.54 |
| Q3 2018 | +685 | Add 0.30% | 232,661 | $312.99 |
| Q4 2018 | -8,323 | Reduce 3.58% | 224,338 | $232.22 |
| Q1 2019 | +16,011 | Add 7.14% | 240,349 | $305.68 |
| Q2 2019 | -9,031 | Reduce 3.76% | 231,318 | $312.59 |
| Q3 2019 | -7,146 | Reduce 3.09% | 224,172 | $332.74 |
| Q4 2019 | +2,326 | Add 1.04% | 226,498 | $370.03 |
| Q1 2020 | -67,684 | Reduce 29.88% | 158,814 | $350.56 |
| Q2 2020 | -86,128 | Reduce 54.23% | 72,686 | $451.49 |
| Q3 2020 | -8,293 | Reduce 11.41% | 64,393 | $515.46 |
| Q4 2020 | -15,082 | Reduce 23.42% | 49,311 | $582.93 |
| Q1 2021 | +1,990 | Add 4.04% | 51,301 | $571.18 |
| Q2 2021 | +833 | Add 1.62% | 52,134 | $644.28 |
| Q3 2021 | -194 | Reduce 0.37% | 51,940 | $745.96 |
| Q4 2021 | +3,810 | Add 7.34% | 55,750 | $755.57 |
| Q1 2022 | +5,986 | Add 10.74% | 61,736 | $563.22 |
| Q2 2022 | +2,167 | Add 3.51% | 63,903 | $495.00 |
| Q3 2022 | +2,762 | Add 4.32% | 66,665 | $417.13 |
| Q4 2022 | -34,769 | Reduce 52.15% | 31,896 | $420.49 |
| Q1 2023 | -99 | Reduce 0.31% | 31,797 | $479.02 |
| Q2 2023 | -27,404 | Reduce 86.18% | 4,393 | $379.12 |
| Q3 2023 | +136 | Add 3.10% | 4,529 | $358.45 |
| Q4 2023 | -52 | Reduce 1.15% | 4,477 | $322.89 |
| Q1 2024 | +60,615 | Add 1353.92% | 65,092 | $345.87 |
| Q2 2024 | +39,095 | Add 60.06% | 104,187 | $273.11 |
| Q3 2024 | +274,508 | Add 263.48% | 378,695 | $334.58 |
| Q4 2024 | +181,829 | Add 48.01% | 560,524 | $328.51 |
| Q1 2025 | +164,136 | Add 29.28% | 724,660 | $243.56 |
| Q2 2025 | +93,964 | Add 12.97% | 818,624 | $241.32 |
| Q3 2025 | -9,144 | Reduce 1.12% | 809,480 | $280.39 |
John Rogers's Bio-Rad Laboratories Investment FAQs
John Rogers first purchased Bio-Rad Laboratories, Inc. (BIO) in Q2 2013, acquiring 1,012,406 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Rogers has held Bio-Rad Laboratories, Inc. (BIO) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Rogers's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q2 2013, adding 1,012,406 shares worth $113.59 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, John Rogers's firm, Ariel Investments, LLC, owns 809,480 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $226.97 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 2.43% of John Rogers's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Rogers's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 1,141,142 shares, as reported at the end of Q1 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.